trb_welcome.jpg

 

The mission of TRB Chemedica Group is to develop innovative and patented pharmaceutical products and medical devices in niche therapeutic areas: rheumatology, ophthalmology and neurology.

vismed.jpgTRB Chemedica S.A. reached agreement with River Plate Biotechnology, Inc. (a subsidiary of Lantibio, Inc.) and Alcon for a license to market, in the United States, a treatment for dry eye based on hyaluronic acid. The candidate product is currently in Phase III clinical studies.

laservis_logo.gif

Smoothing to optimise visual outcomes

LASERVIS® is a viscous masking and wetting solution for use during laser surgery and other surgical procedures.
LASERVIS® contains 0.25% hyaluronic acid whose physical characteristics confer important viscoelastic properties to the product and enables it to be used as a viscous masking agent during laser surgery and as a wetting solution in other surgical procedures.

LASERVIS® is available as 5 single dose units each containing 2 ml of solution.

LASERVIS® is strongly recommended by Ziemer Group AG for use as a masking and wetting solution during surgical procedures with its compact, mobile femtosecond surgical laser FEMTO LDV, for a perfect outcome.

 

laservis_box01.jpgpdf LASERVIS® leaflet
trb_lock.gif Doctor information
Distributors
trb_contact.gifContacts

 
 
  • English